Literature DB >> 19081012

The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer.

Susan C Pitt1, Herbert Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19081012      PMCID： PMC3245622          DOI： 10.1016/j.surg.2008.06.028

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


× No keyword cloud information.
  10 in total

1.  Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

Authors:  C Segouffin-Cariou; M Billaud
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

Review 2.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

3.  Antiproliferative effects of Src inhibition on medullary thyroid cancer.

Authors:  Zijuan Liu; Joy Falola; Xudong Zhu; Ying Gu; Lawrence T Kim; George A Sarosi; Thomas Anthony; Fiemu E Nwariaku
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

4.  Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.

Authors:  D Salvatore; R M Melillo; C Monaco; R Visconti; G Fenzi; G Vecchio; A Fusco; M Santoro
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

Authors:  Muthusamy Kunnimalaiyaan; Mary Ndiaye; Herbert Chen
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

6.  In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer.

Authors:  Abram Vaccaro; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Anticancer Drugs       Date:  2006-08       Impact factor: 2.248

7.  Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells.

Authors:  Muthusamy Kunnimalaiyaan; Abram M Vaccaro; Mary A Ndiaye; Herbert Chen
Journal:  J Biol Chem       Date:  2006-11-07       Impact factor: 5.157

8.  The role of human achaete-scute homolog-1 in medullary thyroid cancer cells.

Authors:  Rebecca S Sippel; Jennifer E Carpenter; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

9.  Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Authors:  Matthias Drosten; Gero Hilken; Miriam Böckmann; Florian Rödicker; Nikica Mise; Aaron N Cranston; Uta Dahmen; Bruce A J Ponder; Brigitte M Pützer
Journal:  J Natl Cancer Inst       Date:  2004-08-18       Impact factor: 13.506

10.  Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.

Authors:  Muthusamy Kunnimalaiyaan; Abram M Vaccaro; Mary A Ndiaye; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261
  10 in total
  10 in total

Review 1.  Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: a brief review.

Authors:  Youngjun Kim; Selina Rahman Shanta; Li-Hua Zhou; Kwang Pyo Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

Review 2.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

3.  MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.

Authors:  Jocelyn F Burke; Logan Schlosser; April D Harrison; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2013-07-31       Impact factor: 5.344

Review 4.  The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.

Authors:  Yash R Somnay; Muthusamy Kunnimalaiyaan
Journal:  Glob J Biochem       Date:  2011-03-08

5.  Vandetanib for the treatment of metastatic medullary thyroid cancer.

Authors:  Nils Degrauwe; Julie Ann Sosa; Sanziana Roman; Hari A Deshpande
Journal:  Clin Med Insights Oncol       Date:  2012-06-07

6.  Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.

Authors:  Vishnu Muthuraj Kumarasamy; Daekyu Sun
Journal:  Int J Oncol       Date:  2017-05-11       Impact factor: 5.650

7.  Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Authors:  Serena Giunti; Alessandro Antonelli; Andrea Amorosi; Libero Santarpia
Journal:  Int J Endocrinol       Date:  2013-02-21       Impact factor: 3.257

8.  Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.

Authors:  Vishnu Muthuraj Kumarasamy; Yoon-Joo Shin; John White; Daekyu Sun
Journal:  BMC Cancer       Date:  2015-08-26       Impact factor: 4.430

Review 9.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Authors:  Helen Louise Robbins; Angela Hague
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-11       Impact factor: 5.555

Review 10.  Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.

Authors:  Aaron C Tan; Malinda Itchins; Mustafa Khasraw
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.